Concizumab: A Breakthrough Prophylaxis for Hemophilia B and A with Inhibitors
The World Federation of Hemophilia (WFH) shared a breakthrough for hemophilia with inhibitors on X:
”While treatment options have advanced, people with hemophilia B and inhibitors still face major gaps. A new review explores concizumab, a subcutaneous prophylaxis option that could help close that gap and improve outcomes.”
Read the full article here.
Despite advancements in hemophilia treatment, people with hemophilia A or B (HA, HB) and inhibitors face significant unmet needs, particularly in prophylaxis.
While emicizumab addresses prophylaxis for HA with inhibitors, no such option existed for HB until the arrival of concizumab.
This novel, subcutaneous treatment—approved since 2023 in countries like Canada, Australia, Japan, and Switzerland—is the first prophylactic therapy for HB with inhibitors.
The drug also offers new hope for HA patients with persistent bleeds on emicizumab.
With a unique mechanism of action, convenient multi-dose pen delivery, and quick washout, concizumab is poised to improve quality of life and long-term outcomes in this historically underserved population.
Hemostasis Today, your daily update on the latest advancements in the field of Hemophilia.
-
Jul 23, 2026, 09:05Fonkou Steve: What If We’ve Been Asking the Wrong Question About Plasma Too?
-
Jul 23, 2026, 08:27Registration Is Now Open for ASH 2026
-
Jul 23, 2026, 08:19Sheeza Nawaz: Why Do Patients With Aortic Stenosis Bleed?
-
Jul 23, 2026, 07:59Paschalis Karakasis: Can Left Atrial Appendage Closure Truly Replace Oral Anticoagulation?
-
Jul 23, 2026, 06:53Lakmali Silva: What Makes ISTH More Than a Scientific Meeting?
-
Jul 23, 2026, 05:48Paschalis Evangelidis: Rethinking Pulmonary Embolism Through the Lens of Thromboinflammation
-
Jul 23, 2026, 05:35Neil Morgan: Honoured to Lead the Platelet and Megakaryocyte Theme at ISTH 2026
-
Jul 23, 2026, 04:42Camilla Oriani: A Memorable First ISTH 2026 in Paris
-
Jul 23, 2026, 03:32Nazlı Pelin Kirkayak: A 9-Year Real-World Analysis of Adult Thrombotic Microangiopathies